Key result
Intracoronary enalaprilat fails to attenuate cardiac noradrenaline spillover during rest or handgrip exercise.
Why the study?
It remains debated whether angiotensin II facilitates noradrenaline release in the human heart and the influence of local intracardiac ACE inhibition on cardiac sympathetic transmission is undetermined.
Does intracoronary enalaprilat infusion reduce cardiac noradrenaline spillover in angina patients with normal left ventricular function?
Does intracoronary enalaprilat infusion reduce cardiac noradrenaline spillover in angina patients with normal left ventricular function?
Intracoronary enalaprilat does not attenuate cardiac sympathetic drive in non-failing human hearts, suggesting no angiotensin II-facilitated effect on cardiac noradrenaline spillover in this population.
Does not support intracoronary enalaprilat to blunt cardiac sympathetic drive in non-failing hearts; leaves open angiotensin II modulation in heart failure.
The present study was designed to identify an interaction between the renin-angiotensin system and noradrenergic transmission in the human heart. It is still under debate whether angiotensin II facilitates noradrenaline release in the heart. Clinical studies of congestive heart failure, involving systemic angiotensin-converting enzyme (ACE) inhibitor administration, have indicated anti-adrenergic effects, without giving a clear mechanistic picture. The influence on cardiac sympathetic transmission by local intracardiac administration of an ACE inhibitor has not been determined. Seven angina patients with normal left ventricular function, who underwent control coronary angiography after successful percutaneous transluminal coronary angioplasty were studied. Baseline measurements of haemodynamics and total and cardiac noradrenaline spillover were followed by handgrip exercise in the absence and presence of intracoronary enalaprilat infusion (0.05 mg min-1, 1 mL min-1). Baseline total body and cardiac noradrenaline spillover remained unchanged following intracoronary enalaprilat infusion, being 3745 +/- 349 and 3896 +/- 257 pmol min-1, and 148 +/- 56 and 149 +/- 55 pmol min-1, before and after drug administration, respectively. Mean arterial pressure, peripheral plasma renin activity and angiotensin II levels were also unaffected by enalaprilat infusion. During handgrip exercise procedures, both total body and cardiac noradrenaline spillover increased substantially, showing no reduction in the presence of intracardiac enalaprilat. Direct administration of the ACE inhibitor enalaprilat to the human heart failed to attenuate cardiac sympathetic drive during baseline conditions or following cardiac adrenergic activation by handgrip exercise. Thus, in the non-failing heart, without chronic adrenergic activation, no angiotensin II-facilitated effect on cardiac noradrenaline spillover could be detected.
No takes yet. Share an insight, caveat, or question.
Rundqvist et al. (1997) studied Angina with normal left ventricular function (n=7). Intracoronary enalaprilat vs. Baseline (absence of enalaprilat) was evaluated on Cardiac noradrenaline spillover (pmol min-1). Intracoronary enalaprilat infusion failed to attenuate cardiac noradrenaline spillover compared to baseline (149 vs 148 pmol min-1) during rest or handgrip exercise.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: